MoonLake CFO sells 17,876 shares under 10b5-1 plan

MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt reported open-market sales of 17,876 Class A ordinary shares.

Rhea-AI Filing Summary

MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt reported open-market sales of 17,876 Class A ordinary shares. The shares were sold on two days at weighted average prices of about $19.60 and $19.68 per share under a Rule 10b5-1 trading plan adopted on December 10, 2025. Following these transactions, he continues to hold 1,154,555 shares directly.

Insider Trade Summary 10b5-1

Net Seller: 17,876 shares

Net Sell 2 txns

Insider Bodenstedt Matthias

Role Chief Financial Officer

Sold 17,876 shs ($352K)

Type	Security	Shares	Price	Value
Sale	Class A ordinary shares, par value $0.0001 per share	2,794	$19.60	$55K
Sale	Class A ordinary shares, par value $0.0001 per share	15,082	$19.68	$297K

Holdings After Transaction: Class A ordinary shares, par value $0.0001 per share — 1,154,555 shares (Direct)

Footnotes (3)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
2. F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.50 to $20.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3. F3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.505 to $19.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Key Figures

Total shares sold: 17,876 shares Shares sold on June 18, 2026: 2,794 shares Shares sold on June 17, 2026: 15,082 shares +4 more

7 metrics

Total shares sold 17,876 shares Net shares sold across two open-market transactions

Shares sold on June 18, 2026 2,794 shares Open-market sale at weighted average price $19.60

Shares sold on June 17, 2026 15,082 shares Open-market sale at weighted average price $19.68

Remaining holdings 1,154,555 shares Class A ordinary shares held directly after transactions

Price range for $19.60 average $19.50–$20.06 Range of individual trade prices for one sale batch

Price range for $19.68 average $19.505–$19.70 Range of individual trade prices for second sale batch

10b5-1 plan adoption date December 10, 2025 Date CFO adopted pre-arranged Rule 10b5-1 trading plan

Key Terms

Class A ordinary shares, Rule 10b5-1 trading plan, weighted average sale price, open-market sale

4 terms

Class A ordinary shares financial

"Class A ordinary shares, par value $0.0001 per share"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported represents the weighted average sale price per share."

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MoonLake Immunotherapeutics (MLTX) disclose?

MoonLake Immunotherapeutics reported that CFO Matthias Bodenstedt sold 17,876 Class A ordinary shares in the open market. The trades occurred on two dates in June at weighted average prices near $19.60 and $19.68 per share under a trading plan.

At what prices did the MoonLake (MLTX) CFO sell his shares?

The CFO’s reported weighted average sale prices were $19.60 and $19.68 per share. Footnotes note the shares were sold in multiple transactions within ranges from $19.50 to $20.06 and from $19.505 to $19.70.

How many MoonLake (MLTX) shares does the CFO hold after these sales?

After the reported open-market sales, CFO Matthias Bodenstedt directly holds 1,154,555 Class A ordinary shares. This figure is disclosed as the total number of shares beneficially owned following the most recent transaction date in the Form 4 filing.

Were the MoonLake (MLTX) CFO share sales under a Rule 10b5-1 plan?

Yes, the filing states the transactions were executed under a Rule 10b5-1 trading plan adopted on December 10, 2025. Such pre-arranged plans allow insiders to sell shares on a preset schedule, reducing discretion over trade timing.

How many MoonLake (MLTX) shares did the CFO sell on each date?

The CFO sold 2,794 shares on June 18, 2026 at a weighted average price of $19.60, and 15,082 shares on June 17, 2026 at a weighted average price of $19.68, according to the Form 4 transaction table.

What trading ranges did the MoonLake (MLTX) CFO’s share sales cover?

Footnotes explain the sales at $19.60 averaged across trades from $19.50 to $20.06. The $19.68 average reflects trades between $19.505 and $19.70. The CFO will provide detailed breakdowns upon appropriate request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 06:45 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bodenstedt Matthias

(Last) (First) (Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG 6300

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A ordinary shares, par value $0.0001 per share	06/17/2026		S(1)		15,082	D	$19.68(2)	1,157,349	D
Class A ordinary shares, par value $0.0001 per share	06/18/2026		S(1)		2,794	D	$19.6(3)	1,154,555	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.50 to $20.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.505 to $19.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

	/s/ Matthias Bodenstedt	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)